Aquestive Therapeutics In... (AQST)
Bid | 2.64 |
Market Cap | 270.17M |
Revenue (ttm) | 54.23M |
Net Income (ttm) | -54.24M |
EPS (ttm) | -0.58 |
PE Ratio (ttm) | -4.69 |
Forward PE | -4.72 |
Analyst | Buy |
Ask | 2.8 |
Volume | 674,624 |
Avg. Volume (20D) | 1,444,545 |
Open | 2.77 |
Previous Close | 2.79 |
Day's Range | 2.65 - 2.75 |
52-Week Range | 2.12 - 5.80 |
Beta | 2.02 |
About AQST
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for AQST stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
2 weeks ago · seekingalpha.com
Aquestive Therapeutics, Inc. (AQST) Q1 2025 Earnings Call TranscriptAquestive Therapeutics, Inc. (NASDAQ:AQST ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of S...

2 months ago · seekingalpha.com
Aquestive Therapeutics: Oral Anaphylaxis NDA Opportunity Spells BuyAquestive currently plays small ball with a handful of approved products that offer no adequate financial potential. Its recently approved Libervant, which offered greater revenue opportunity, is mire...

2 months ago · seekingalpha.com
Aquestive Therapeutics, Inc. (AQST) Q4 2024 Earnings Call TranscriptAquestive Therapeutics, Inc. (NASDAQ:AQST ) Q4 2024 Results Conference Call March 6, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of S...